N/A N=60 Urinary Cytokines in Patients With Overactive Bladder (OAB)
Overactive Bladder · Urinary Tract Infection
Primary: Number of Participants With Elevated Cytokines (Levels of Pro-inflammatory) — 20; 20; 16 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=20 Hypnotherapy for Treatment of Overactive Bladder
Overactive Bladder
Primary: Change in Overactive Bladder Symptoms (Based on OABqSF) — -19; -33.4 units on a scale — p=.07
N/A N=18 Pilot Study: Is Overactive Bladder Caused by Subacute Urinary Tract Infections?
Overactive Bladder
Primary: Number of Subjects With Evidence of Bacteria in Urine Sample by Microbiologic Evaluation — 8; 1 participants
Phase 3 N=143 Behavioral Treatment of Overactive Bladder in Men
Overactive Bladder
Primary: 24-hour Voiding Frequency — 9.1; 9.5 voids per 24-hour day — p=.001
Phase 4 N=254 OnabotulinumtoxinA (BOTOX®) Treatment for Urinary Incontinence in Patients With Overactive Bladder
Overactive Bladder
Primary: Percentage of Participants Who Achieve a 100% Reduction in Urinary Incontinence Episodes — 32.0; 7.2 percentage of participants
Phase 4 N=100 Overactive Bladder Innovative Therapy Trial (OrBIT)
Overactive Bladder
Primary: Frequency of Voids at 12 Weeks — -2.4; -2.5 Voids/day
N/A N=20 A Trial of Transcutaneous Nerve Stimulation for OAB
Overactive Bladder
Primary: Patient Reported Outcome Measure (Patient Percention of Bladder Condition Question) — 4; 3 units on a scale
Phase 4 N=84 Mirabegron and Urinary Urgency Incontinence
Overactive Bladder
Primary: Response to Therapy — 15; 29 Participants
Phase 2 N=383 BOTOX® Intravesical Instillation in Participants With Overactive Bladder and Urinary Incontinence
Urinary Incontinence · Overactive Bladder With Urinary Incontinence
Primary: Stage 2: Change From Baseline in the Average Number of Urinary Incontinence Episodes (UIEs) Per Day — -2.72; -1.62; -0.89; -1.52 episodes per day — p=0.0845
Phase 2 N=9 Botulin-A Toxin Instillations and Overactive Bladder
Overactive Bladder · Detrusor Instability · Detrusor Hyperreflexia
Primary: Median Number of Incontinent Episodes During 24 Hours — 4; 2; 4 number of incontinent episodes — p=0.004
Phase 3 N=356 A Study Evaluating the Efficacy and Safety of BOTOX® or Solifenacin in Patients With Overactive Bladder and Urinary Incontinence
Overactive Bladder · Urinary Incontinence
Primary: Change From Study Baseline in Number of Episodes of Urinary Incontinence in Treatment Cycle 1 — 4.86; 5.23; 4.38; -3.10 Incontinence Episodes
Phase 2 N=80 URO-902 in Female Subjects With Overactive Bladder and Urge Urinary Incontinence
Overactive Bladder With Urge Urinary Incontinence
Primary: Change From Baseline at Week 12 in Average Daily Number of Urgency Episodes — -1.13; -2.43; -3.37 Urgency episodes per day — p==0.1722
N/A N=21 Comparative Urine Proteomic Studies of Overactive Bladder in Humans
Overactive Bladder
Primary: Bladder Diary to Assess Urinary Frequency at Baseline and at End of 6-week Treatment — 12.32; 10.79 urinations/day — p=0.19
Phase 3 N=58 Pilot Study of Mirabegron in Pediatric Patients With Overactive Bladder
Overactive Bladder · Urinary Incontinence
Primary: Improved Overactive Bladder Symptoms as a Measure of Efficacy of Mirabegron — 13; 14; 25; 6 Participants
N/A N=8 Utilization of the BIOWAVE Device to Treat Overactive Bladder
Overactive Bladder
Primary: Global Response Assessment (GRA) — 5.25; 4; 4.6; 5.1 units on a scale
Phase 3 N=35 Add-on Mirabegron in Pediatric Patients With Refractory Overactive Bladder
Overactive Bladder · Urinary Incontinence
Primary: Response to Urinary Incontinence as a Composite Measure of Efficacy of add-on Mirabegron — 12; 23 Participants
Phase 3 N=249 Anticholinergic vs. Botox Comparison Study
Urge Urinary Incontinence · Overactive Bladder
Primary: Change in Urge Urinary Incontinence (UUI) Episodes — -3.13; -3.15; -3.32; -3.25 Mean change in UUI episodes from baselin
Phase 1 N=51 Study of V117957 in Overactive Bladder Syndrome
Overactive Bladder Syndrome
Primary: Change From Baseline in Micturition Episode Components (Micturition, Incontinence, and Urgency) Per 24 Hours. — -0.8; -0.8; -0.2; -0.4 Episodes per 24 hours
Phase 3 N=548 Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence
Overactive Bladder
Primary: Change From Baseline in Number of Daily Episodes of Urinary Incontinence — 5.52; 5.70; -2.95; -1.03 Incontinence episodes
N/A N=18 Posterior Tibial Nerve Stimulation's Effectiveness in UI Frequency in Overactive Patients in Home
Overactive Bladder
Primary: Change in Urge Incontinence Episodes — 3.9 UUI
Phase 1 N=20 A Study to Test the Effects of Tolterodine Tartrate in Patients With Overactive Bladder (0000-107)
Overactive Bladder
Primary: Change From Baseline in Maximum Cystometric Capacity at 4 Hours Post Dose 7 on Tolterodine 4 mg and Placebo — 1.15; 0.94 Percentage change — p=0.008
N/A N=150 The Effect of Urox™ in the Treatment of Overactive Bladder and Urinary Incontinence
Overactive Bladder · Urinary Incontinence · Urinary Frequency or Urgency Adverse Event
Primary: Day Urinary Frequency — 7.68; 10.95 number of diurnal micturitions per day
Phase 2 N=313 A Research Study for Patients With Overactive Bladder
Overactive Bladder · Urinary Incontinence
Primary: Change in Number of Urinary Urge Incontinence Episodes — 32.5; 30.3; 27.8; 28.3 episodes
Phase 4 N=120 Evaluation of an Alternative Injection Paradigm for OnabotulinumtoxinA (BOTOX®) in the Treatment of Overactive Bladder in Patients With Urinary Incontinence
Urinary Bladder, Overactive · Urinary Incontinence
Primary: Change From Baseline in Daily Average Number of Urinary Incontinence Episodes — -2.99; -0.42 incontinence episodes per day — p=<.0001
N/A N=20 Amplifying Sensation in Underactive Bladder
Urinary Bladder, Underactive
Primary: Voiding Efficiency — 32; 53; 43; 46 voided percentage — p=1
Phase 4 N=54 Posterior Tibial Nerve Stimulation (PTNS) Plus Mirabegron to Treat Refractory OAB Symptoms (PTNS-M Study)
Overactive Bladder
Primary: Change in the Number of UUI Episodes Over a 3-day Voiding Diary Pre- vs. Post-treatment. This Includes a Baseline Measure Pre-trial and a Pos-trial Measure in 12 Weeks…
Phase 3 N=947 Fesoterodine "add-on" Male Overactive Bladder Study
Overactive Bladder Syndrome
Primary: Numerical Change From Baseline in Micturition-Related Urgency Episodes Per 24 Hours at Week 12 — -3.2; -2.9 number of episodes — p=0.1959
Phase 4 N=547 Study of 2 Doses of Solifenacin Succinate in Female Subjects With Overactive Bladder.
Detrusor Overactivity · Overactive Bladder
Primary: Change From Baseline to Week 12 in Bladder Wall Thickness — 0.00; -0.29; -0.18; -0.24 mm — p=0.095
Phase 4 N=249 A Study With Mirabegron 50 mg and 25 mg in Chinese Participants With Overactive Bladder
Urge Incontinence · Overactive Bladder (OAB)
Primary: Change From Baseline (CFB) to the End of 12-Week Treatment Period in Mean Number of Micturition/24 Hours in Mirabegron 50 mg Group — -3.76 micturitions per 24 hours…
N/A N=96 FREEOAB Study for Overactive Bladder
Overactive Bladder · Urinary Frequency · Urinary Incontinence, Urge
Primary: Percentage of Responders in Voiding (Urinary Frequency) Events — 55 Participants